Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026GlobeNewsWire • 04/15/26
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition RisksThe Motley Fool • 03/07/26
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular DiseaseGlobeNewsWire • 02/23/26
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category CommercializationGlobeNewsWire • 01/09/26
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk PatientsGlobeNewsWire • 11/09/25
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025GlobeNewsWire • 11/03/25
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular CongressGlobeNewsWire • 10/14/25
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?Zacks Investment Research • 10/06/25
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025GlobeNewsWire • 08/31/25
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient SubgroupsGlobeNewsWire • 08/30/25
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025GlobeNewsWire • 08/25/25
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/14/25